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Abstract
Background: Infections caused by extended-spectrum beta-lactamases producing Enterobacteriaceae (ESBL-E) are of
major concern in clinical practice because of limited therapeutic options effective to treat them. Published studies
showed that ESBL-E, widely spread in Europe, United States or Asia; are also frequent in Africa. However, the impact
of ESBL-E infections is yet to be adequately determined in Sub-Saharan African countries, particularly in Senegal.
The aim of our study was to estimate the incidence rate of ESBL-E infections and to assess their clinical and
economic impact in Senegal.
Methods: Two retrospective cohort studies were conducted in patients hospitalized from April to October 2012.
A classic retrospective cohort study comparing patients infected by an Enterobacteriaceae producer of ESBL (ESBL+)
and patients infected by an Enterobacteriaceae non-producer of ESBL (ESBL-) was carried out for fatal outcomes.
Besides, a retrospective parallel cohort study comparing infected patients by an ESBL+ and ESBL- versus uninfected
patients was carried out for the excess LOS analyses. Multivariable regression analysis was performed to identify risk
factors for fatal outcomes. A multistate model and a cost-of-illness analysis were used to estimate respectively the
excess length of stay (LOS) attributable to ESBL production and costs associated. Cox proportional hazards models
were used to assess the independent effect of ESBL+ and ESBL- infections on LOS.
Results: The incidence rate of ESBL-E infections was 3 cases/1000 patient-days (95 % CI: 2.4–3.5 cases/1000 patient-days).
Case fatality rate was higher in ESBL+ than in ESBL- infections (47.3 % versus 22.4 %, p = 0.0006). Multivariable analysis
indicated that risk factors for fatal outcomes were the production of ESBL (OR = 5.7, 95 % CI: 3.2–29.6, p = 0.015) or
being under mechanical ventilation (OR = 5.6, 95 % CI: 2.9–57.5, p = 0.030). Newborns and patients suffering from
meningitidis or cancer were patients at-risk for fatal outcomes. ESBL production increased hospital LOS (+4 days) and
reduced significantly the hazard of discharge after controlling for confounders (HR = 0.3, 95 % CI:0.2–0.4). The additional
cost associated with ESBL-production of €100 is substantial given the lower-middle-income status of Senegal.
Conclusion: Our findings show an important clinical and economic impact of ESBL-E infections in Senegal and
emphasize the need to implement adequate infection control measures to reduce their incidence rate. An antibiotic
stewardship program is also crucial to preserve the effectiveness of our last-resort antibiotic drugs.
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Background
Extended-spectrum beta-lactamases producing Entero-
bacteriaceae (ESBL-E) are of major concern since infec-
tions caused by these resistant strains are associated
with prolonged hospital stay and increased case-fatality
rate [1–3]. ESBL-E became a significant therapeutic
challenge worldwide in daily clinical practice since their
resistances to additional classes of antibiotics reduce ef-
fective therapeutic options [4–6]. However, the increased
use of carbapenems, drugs of last-resort to treat these
infections, favors the emergence of carbapenem-resistant
Enterobacteriaceae [7–9]. It is therefore crucial to better
understand the extent of the threat poses by ESBL-E and
to quantify its burden in order to help policymakers and
healthcare professionals to set priorities and implement
effective countermeasures. In Africa published studies
showed that ESBL-E prevalence rate is increasing and is
varying from 0.7 % in Malawi to 75.8 % in Egypt [10, 11].
However, until now the burden of ESBL-E has not been
clearly established especially in sub-Saharan African
countries.
This study aimed to estimate the incidence rate of
ESBL-E infections and to assess the clinical and eco-
nomic consequences of these infections in two hospitals
in Dakar, Senegal.
Methods
Study design and population
Two retrospective cohort studies were carried out in pa-
tients hospitalized from April to October 2012 at the
University Hospital of Fann and Albert Royer Children’s
hospital, 2 academic tertiary care hospitals located in the
same geographic area in Dakar, Senegal (respectively a
339-Bed and 120-bed hospitals). A classic retrospective
cohort study comparing patients infected by an Entero-
bacteriaceae producer of ESBL (ESBL+) and patients in-
fected by an Enterobacteriaceae non-producer of ESBL
(ESBL-) was carried out for fatal outcomes. Besides, a
retrospective parallel cohort study comparing infected
patients (ESBL+ or ESBL- infections) versus uninfected
patients was carried out for excess LOS analyses. Pa-
tients with an infection caused by an Enterobacteriaceae
strain were identified through a laboratory-based surveil-
lance of strains recovered from diagnostic samples taken
at least 48 h after the patient admission when an infec-
tion was suspected. The date of the infection onset was
the date the first sample yielding an Enterobacteriaceae
strain was collected. If a bacterial strain was isolated on
several occasions, only the first isolation was considered.
Uninfected patients were randomly selected from the
hospital database system. Inclusion criteria for the group
of uninfected patients were the absence of clinical signs
of an infection reported in patients’ medical files, the
absence of diagnostic samples drawn and antibiotics
prescriptions during the hospital stay. Infected and unin-
fected patients were matched on ward and day of admis-
sion. All patients included in the study were followed
from admission to discharge or in-hospital death. For
each patient, the following variables were collected:
gender, age, germs isolated and their resistance profile,
underlying comorbidities, diagnostic at admission, inter-
ventions related to patient care before the infection
onset, length of stay, date of infection onset, antibiotic
prescriptions during the hospital stay and in-hospital
mortality.
Definitions
Newborns were defined as patients less than 28 days of
life and included premature babies (babies born before
37 weeks of gestational age). Children were patients aged
between 1 month and 16 years and adults were patients
up to 16 years.
An infection was suspected if clinical signs of the
infection were observed by the clinician and was
bacteriologically confirmed when a bacterial strain was
recovered from diagnostic samples. In newborns and chil-
dren, an infection was suspected in the presence of fever
(> = 38 °C), hypothermia (<36 °C) or other signs of infec-
tion as detailed in the World Health Organization (WHO)
guideline of the Integrated Management of Childhood
Illness [12]. Infections were defined as ESBL+ when the
sample yielded an ESBL-producing Enterobacteriaceae
(ESBL-E) and ESBL- when Enterobacteriaceae was non-
producer of ESBL. Antimicrobial therapy was defined as
empirical if prescribed initially before susceptibility tests
results were available. Initial antibiotic therapy was con-
sidered as inadequate when the empirical antibiotic drug
was not active against the pathogen causing the infection.
Microbiological methods
Enterobacteriaceae strains were Gram strained and then
identified with API 20E strips (bioMérieux, Marcy
l’Etoile, France). Susceptibilities against antimicrobial
agents and the detection of ESBL production were rou-
tinely performed in the two hospitals by the disc diffu-
sion synergy method using discs containing cefepime,
ceftazidime and cefotaxime each placed 30 mm apart
around a disc containing clavulanic acid as recom-
mended by the Antibiogram Committee of the French
Microbiology Society [13].
Statistical analysis
Continuous variables were compared using Student’s t
test with unequal variances. Fisher’s exact test was used
for the comparison of categorical variables.
To evaluate risk factors for fatal outcomes, a multivari-
able model was constructed using a backward stepwise
logistic regression analysis including all variables with a
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p-value less than 0.20 in the univariate analysis. P value
less than 0.05 was considered as significant.
Multistate model
The excess LOS attributable to ESBL production was es-
timated using a multistate model in which the occur-
rence of the infection was the time-dependent exposure,
while the discharge (alive or dead) was the study end-
point (Fig. 1). Patients enter in the multistate model in
state 1 at hospital admission. At the time of infection
(ESBL+ or ESBL- infection) patients move to state 2
then to state 3 at the time of discharge or death. Patients
who do not experience an infection during their hospital
stay move directly from state 1 to state 3. The excess
LOS attributable to ESBL production was the difference
between LOS due to ESBL+ and ESBL- infections. When
assessing the LOS due to ESBL+ infections, patients with
an ESBL+ infection were compared to patients free of
infection including uninfected patients and patients with
an ESBL- infection but the latter were administratively
censored at the time of infection. Likewise, patients with
an ESBL+ infection were administratively censored when
assessing the LOS due to ESBL- infection [14, 15].
Transition probabilities to move from one state to an-
other were estimated non-parametrically using the Aalen-
Johansen estimator [15–17]. The expected LOS was then
computed by a function of the Aalen-Johansen estimator
for the matrix of transition probabilities. The mean differ-
ence in LOS was computed for each day in the interval, as
the difference between the estimated LOS given the inter-
mediate state had been reached or not up that day. Stand-
ard errors and confidence intervals were calculated by 500
bootstrap resampling runs [15, 18, 19].
To assess the independent effect of ESBL+ and ESBL-
infections on LOS, they were separately evaluated as
time-dependent covariates using Cox proportional haz-
ards modeling to estimate the end-of-LOS hazard ratio
(HR). Variables for adjustment included age, comorbidi-
ties and invasive devices.
The R packages msm and etm were used for LOS ana-
lysis (version 2.15.3). All other statistical analyses were
performed using Stata software, release 13.0.
Cost-of-illness analysis
A cost-of-illness (COI) analysis was performed to quan-
tify the cost associated with ESBL production from the
patient perspective. Only direct medical costs incurred
by patients from the date of the infection onset were
measured. Indirect costs such as lost wages resulting
from death or the absence from work were not consid-
ered in our analysis. A bottom-up approach was used to
calculate the resources spent to treat the infection.
Therefore total cost related to an infection (ESBL+ or
ESBL+ infection) included costs of hospital stay, labora-
tory diagnostic tests and antibiotic drugs prescriptions.
The cost of the hospital stay was calculated by multiplying
the excess LOS attributable to the infection (estimated by
multistate modeling) by the bed-day cost. For the costs re-
lated to diagnostic tests we considered the inclusive fee of
€25 charged for all laboratory tests performed on a patient
during the hospital stay, regardless of their number and
nature. The dosage and duration of antibiotic drugs
prescriptions to treat the infection were collected from pa-
tients’ medical files. The drug prices used for the calcula-
tions differ according to whether drugs were bought at the
subsidized hospital pharmacy or purchased in private
pharmacies.
Ethical considerations
This study protocol was approved by the hospital’s institu-
tional review board. Since the data were routinely col-
lected and anonymized, ethical consent was not required.
Results
Characteristics of the study patients
During the 6-month study period, 186 Enterobacteriaceae
strains were isolated in patients with a suspected infection.
ESBL-E (n = 110) were Klebsiella spp (49.1 %), Enterobacter
Fig. 1 Multistate model used for the excess length of stay analysis. Every patient enters the model in state 1 on the day of admission, make a
transition into state 2 at the time of infection (ESBL+ or ESBL-) then move to the 3 at the time of discharge or death. Uninfected patients enter in
state 1 and move to state 3 without transition through state 2
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spp (28.2 %) and E.coli (22.7 %). The incidence rate of
ESBL-E was 3 cases/1000 patient-days (95 % CI: 2.4–3.5
cases/1000 patient-days). The characteristics of the study
patients are described in Table 1. The study population
was constituted of 110 patients with an ESBL+ infection,
76 patients with an ESBL- infection and 186 uninfected pa-
tients. ESBL-E was most frequently associated with blood-
stream infections (44.5 %), urinary tract infections (32.7 %)
and surgical site infections (11.8 %) (Table 1).
Fatal outcomes
Sixty-nine patients with an infection caused by an
Enterobacteriaceae died during the study period (37.1 %).
The case-fatality rate was significantly higher in ESBL+
(47.3 %) than in ESBL- infections (22.4 %) (p = 0.0006).
Patients who died were most frequently newborns, prema-
ture babies, patients who suffered from meningitidis or
cancer, patients with an ESBL+ infection and patients with
invasive devices such as mechanical ventilation or central
venous catheter (Table 2).
Multivariable analysis showed that the production of
ESBL (OR = 5.3, 95 % CI: 3.1–19.9, p = 0.008) or being
under mechanical ventilation (OR = 6.1, 95 % CI: 3.1–
124.6, p = 0.004) were independent risk factors for fatal
outcomes. Results also showed that newborns and pa-
tients suffering from meningitidis or cancer were pa-
tients at-risk for fatal outcomes (Table 2).
Length of stay (LOS)
Then mean LOS associated with ESBL+ and ESBL- infec-
tions was respectively 22.6 days (95 % CI: 20.3–24.9 days)
and 14 days (95 % CI: 11.9–16.2 days). The mean
time to infection was significantly longer in patients
with an ESBL+ than an ESBL- infection except in
newborns (Table 1). However, when comparing patient’s
groups, the mean time to infection was shorter in new-
borns (3.5 days) than in children (6.6 days) or adults
(11.3 days). Besides, the hospital stay after the infection
was significantly longer in ESBL+ than in ESBL- infections
(14.4 versus 9.3, p < 0,0001) suggesting that ESBL produc-
tion prolonged the hospital LOS. Results presented in
Table 1 Baseline characteristics of patients infected by
Enterobacteriaceae producer of ESBL (ESBL+) and
Enterobacteriaceae non-producer of ESBL (ESBL-)






Male gender 68(61.8) 35(46.05) 0.037
Mean age, years (range) 26.3(20.9–31.7) 28.1(21.5–34.7) 0.665
Newborns (0–28 days) 22(20.0) 4(5.3) 0.005




Adults (up to 17 years) 51(46.4) 38(50.0) 0.656
Comorbidity
Sickle cell disease 10(9.1) 7(9.2) 1
Malnutrition 10(9.1) 7(9.2) 1
AIDS 8(7.2) 2(2.6) 0.203
Diagnostic at admission
Severe malaria 19(17.3) 7(9.2) 0.808
Gastroenteritis 16(14.5) 9(11.8) 0.666
Respiratory disease 25(22.7) 10(9.1) 0.127
Neurologic disorder 20(18.2) 12(15.8) 0.698
Meningitis 10(9.1) 5(4.5) 0.596
Tuberculosis 3(2.7) 3(3.9) 0.689
Cancer 10(9.1) 6(7.9) 1
Tetanus 4(3.6) 6(7.9) 0.321
Invasive procedure
Surgical intervention 18(16.4) 18(23.7) 0.258
Parental nutrition 24(21.8) 6(7.9) 0.014
Mechanical ventilation 38(34.5) 7(9.2) <0.0001
Central venous catheter 84(76.4) 35(46.0) <0.0001
Urinary catheter 37(33.6) 13(17.1) 0.018
Type of infection
Bloodstream infection 49(44.5) 20(26.3) 0.013
Urinary tract infection 36(32.7) 31(40.8) 0.279
Surgical site infection 13(11.8) 11(14.4) 0.656
Respiratory infection 5(4.5) 12(15.8) 0.016
Meningitidis 7(6.4) 2(2.6) 0.313
Time to infection,
in days (95%CI)
All patients 8.2(6.4–9.9) 4.8(2.7–6.9) 0.007
Adults 11.3(8.8–13.8) 7.7(4.8–10.6) 0.029
Children 6.6(3.1–10.2) 2(1.2–5.2) 0.028
Newborns 3.5(2.2–4.8) 1(0.3–2.3) 0.059
Table 1 Baseline characteristics of patients infected by
Enterobacteriaceae producer of ESBL (ESBL+) and
Enterobacteriaceae non-producer of ESBL (ESBL-) (Continued)
Mean time after infection,
days (95 % CI)
All patients 14.2(12.6–16.3) 9.3(7.4–11.1) <0.0001
Adults 15.1(11.9–18.3) 8.9(7.2–10.6) 0.001
Children 15.5(12.3–18.7) 10(6.3–13.7) 0.013
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Table 3 indicated that ESBL production was associated
with an excess LOS of 4 days (95 % CI: 3.8–4.6) and de-
creased significantly the hazard of discharge after adjust-
ment for confounding (HR:0.3, 95 % CI:0.2–0.4). However,
ESBL- infections did not decrease significantly the hazard
of being discharged (HR:0. 9, 95 % CI:0. 7–1.2).
Cost-of-illness analysis
The cost-of-illness (COI) analysis indicated a mean hos-
pital cost significantly greater in ESBL+ (€215, 95 % CI:
€196–233) than in ESBL- infections (€115, 95 % CI:
€103–123), p < 0.0001. Thus, the additional cost attribut-
able to ESBL production was €100 (95 % CI: €78–€125).
Hospital stay and antibiotic drugs accounted respectively
for 60 and 40 % of this cost.
Discussion
Our study quantifies the economic impact of ESBL-E
infections in patients admitted in 2 hospitals in Senegal.
The additional cost of €100 attributable to the ESBL
Table 2 Risk factors for fatal outcomes: results of univariate and multivariable analyses
Variable, n (%) Fatal outcomes Univariate analysis Multivariable analysis
Yes (n = 69) No (n = 117) OR 95 % CI P-value OR 95 % CI P-value
Demographics
Male gender 34(49.3) 49(41.9) 1.3 0.7–2.4 0.361
Mean age, years (range) 27.1(20.4–33.8) 26.9(21.6–32.3) 0.489
Newborns (0–28 days) 16(23.2) 10(8.5) 3.2 1.4–7.5 0.008 4.5 2.4–37.8 0.025
P remature babies 9(13.0) 5(4.3) 3.4 1.1–9.9 0.042
Children (1 month–17 years) 17(24.6) 54(46.1) 2.6 1.4–5.0 0.005
Adults (up to 17 years) 36(52.2) 53(45.3) 1.3 0.7–2.4 0.448
Comorbidity
Sickle cell disease 6(8.7) 11(0.5) 0.5 0.3–2.5 1
Malnutrition 4(5.8) 13(11.1) 0.5 0.5–1.5 0.296
AIDS 3(4.3) 7(5.9) 0.7 0.2–2.6 0.747
Diagnostic at admission
Gastroenteritis 6(8.7) 19(16.2) 0.5 0.2–1.3 0.184
Respiratory disease 18(26.1) 17(14.5) 2.1 0.9–4.3 0.079
Meningitis 11(15.9) 4(3.4) 5.3 1.7–16.6 0.004 2.3 1.5–4.9 <0.0001
Tuberculosis 2(2.8) 4(3.4) 0.8 0–4.1 1
Cancer 12(20.3) 4(3.4) 5.9 1.9–18.3 0.002 2.7 1.6–6.6 0.001
Neurologic disorder 8(11.5) 24(20.5) 0.5 0.2–1.2 0.159
Invasive procedure
Surgical intervention 15(21.7) 21(17.9) 1.3 0.6–2.6 0.567
Parenteral nutrition 15(21.7) 15(12.8) 1.9 0.9–4.1 0.148
Mechanical ventilation 28(40.5) 17(14.5) 3.9 1.9–7.9 0.0002 6.1 3.1–124.6 0.040
Central venous catheter 53(76.8) 66(56.4) 2.6 1.3–4.9 0.007
Urinary catheter 14(20.3) 36(30.8) 0.6 0.3–1.1 0.128
ESBL Production 52(75.4) 58(49.6) 3.1 1.6–5.9 <0.0001 5.3 3.1–19.9 0.008
Type of infection
Bloodstream infection 31(44.9) 38(32.5) 1.7 0.9–3.1 0.116
Urinary tract infection 18(26.1) 49(41.9) 0.5 0.2–0.9 0.039
Meningitidis 7(10.1) 2(1.7) 6.5 1.5–25.7 0.014
Surgical site infection 9(13.0) 15(12.8) 1.0 0.4–2.4 1
Respiratory infection 4(6.8) 8(7.7) 0.8 0.2–2.7 1
Inadequate antibiotherapy prescription 49(71.0) 62(52.9) 2.3 1.2–4.3 0.013
Mean time to infection, days, (95 % CI) 5.9(4.3–7.5) 7.3(5.4–9.3) 0.838
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production may appear as low compared to costs re-
ported in high-income countries, which vary from €5,
000 to €14, 720 [1, 2, 20, 21]. The difference in costs
could be explained firstly by the high cost of equipment
used in high-income countries, and secondly by the vari-
ability in methods used to estimate the economic impact
of ESBL-E infections. Indeed, the occurrence of the in-
fection considered as time-fixed in studies that compare
infected patients with uninfected patients and the use of
median values have been demonstrated to overestimate
costs [22]. We avoided those pitfalls in our cost-of-illness
(COI) analysis by comparing patients with ESBL+ and
ESBL- infections versus uninfected patients, by consider-
ing the infection as time-dependent and measuring mean
values. Costs were estimated from the patient’s perspective
and not from the hospital or third-party payer perspective
as frequently found in the literature. Indeed in Senegal,
hospital costs are most of the time entirely outlaid by pa-
tients since only 20 % of the population has a healthcare
coverage. Costs associated with ESBL+ or ESBL- infec-
tions might be considerable for some patients, since these
costs are respectively 2.5-times and 1.3-times higher than
the mean monthly salary (€87) in the country [23]. These
out-of-pocket expenses can be crippling for already-
impoverished households, pushing them further into pov-
erty [24, 25]. Kruk et al. demonstrated that 37.8 % (95 % CI:
30.7–45.5) of Senegalese households often resort to “hard-
ship financing” defined as borrowing money from family,
friends or selling their assets to cover hospital costs [26].
Besides, the hospital charges attributable to ESBL pro-
duction would be more burdensome if antimicrobial
therapy such as imipenem was prescribed. A 7-day treat-
ment by imipenem would lead to an additional cost of
€400. The choice of appropriate antibiotic drugs is cru-
cial to treat ESBL-E infections; however, hospital stay
was found to be the major driver of costs and could rep-
resent up to 60 % of costs as previously shown [21]. The
time-dependent nature of infections should be taken into
account when assessing the excess LOS attributable to a
multidrug resistant pathogen. Indeed, it has been shown
that the time-dependent bias will inevitably overestimate
the impact of the infection on LOS and consequently on
hospital costs [27, 28]. Therefore, we used a multistate
model that accounts for time-varying exposure thereby
avoiding the time-dependent bias inherent in other com-
monly used statistical methods [15, 28–30]. Results of the
multistate model revealed an excess LOS attributable to
ESBL production of 4 days (95 % CI: 3.8–4.6). Results of
the Cox proportional hazards models showed a significant
reduction in hazard of discharge associated with ESBL+
infections after adjustment on confounders and conse-
quently a prolonged hospital stay.
Furthermore, the high rate of inadequate initial anti-
microbial therapy (IIAT) in ESBL+ infections might
delay the initiation of adequate therapy and conse-
quently explain the prolonged LOS and the significant
impact of ESBL+ infections on fatal outcomes demon-
strated in our study [31, 32]. Indeed, the unavailability of
imipenem in pharmacies or its unaffordability to the
majority of patients may increase the risk of therapeutic
failure in severe ESBL+ infections and thereby the risk
of fatal outcomes. Our results suggest to adapt the
current antibiotic prescriptions’ guidelines to the local
bacterial epidemiology and to restrict the frequent
empirical use of 3rd generation cephalosporins.
The multistate model can be considered as a suitable
approach when assessing the excess LOS attributable to
ESBL production. However, while taking into account
the time-dependent bias, the excess LOS may still be
biased by other covariates. Besides, our findings should
be interpreted with cautious since we could not collect
data on prior antibiotic exposure that may potentially
underestimate the incidence rate of ESBL+ infections.
Additionally our results cannot be generalized to the
whole hospitals in Senegal since our study was carried
out only in two hospitals.
Despite these limitations, our findings should increase
the awareness of healthcare decision makers on the
threat poses by ESBL-E infections. Besides, these results
should incite them to implement adequate infection pre-
vention and control policies to reduce the incidence rate
and the clinical and economic impact of ESBL-E infec-
tions. The assessment of the level of hand hygiene prac-
tices realized during the study period in the two hospital
settings using a WHO tool [33] showed a basic level of
hand hygiene suggesting that some measures were in
place but not to a satisfactory standard. An infection
control program including the promotion of alcohol-
based handrub (ABHR) use should be implemented in
these hospitals in order to improve their hand hygiene
levels and to decrease the incidence rate of ESBL-E
infections. Indeed, hand washing using alcohol-based
handrub (ABHR) has been shown to be successful to
reduce the incidence rate of antimicrobial resistant
Table 3 Estimation of the excess length of stay (LOS) and









ESBL+ infectiona 7.9 (7.6–9.2) 0.3 (0.2–0.4) 0.3 (0.2–0.4)
ESBL- infectionb 3.9 (3.8–4.6) 0.9 (0.7–1.2) 0.9 (0.7–1.2)
CI confidence interval
aModel A: Excess LOS due to ESBL+ infection
110 patients with ESBL+ infection versus 76 patients with ESBL- infection
censored at time of infection and 186 uninfected patients
bModel B: Excess LOS due to ESBL- infection
Seventy-six patients with ESBL- infection versus 110 patients with ESBL+ infection
censored at time of infection and 186 uninfected patients
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pathogens [34–36]. To ensure the availability of expensive
ABHR in resource-poor countries, the WHO African
Partnerships for Patient Safety program have launched a
program in the two study settings for the local production
of ABHR [37]. Additionally, since the human digestive
tract is the main reservoir of Enterobacteriaceae strains,
measures specifically targeting ESBL-E, such as the man-
agement of excreta, should also be implemented.
Conclusion
We show that ESBL-E are frequent in Senegal and that in-
fections caused by these multiresistant pathogens increase
the case-fatality rate and the hospital length of stay of
hospitalized patients and consequently have an important
financial impact for patients. Our findings are a call for
action to healthcare policymakers to consider multidrug
resistance as a national health priority and to implement
adequate infection control measures to tackle this world-
wide issue. Surveillance surveys should be implemented in
Sub-Saharan African countries in order to have a more ac-
curate estimate of the global extent of ESBL-E, which
threaten the effectiveness of our last-resort drugs.
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